# A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg

> **NCT02091986** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 882 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Symbicort pMDI
- **DRUG:** Symbicort pMDI
- **OTHER:** Budesonide pMDI

## Key facts

- **NCT ID:** NCT02091986
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 882 (ACTUAL)
- **Last updated:** 2017-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02091986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02091986, "A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02091986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*